IN2014CN04734A - - Google Patents

Info

Publication number
IN2014CN04734A
IN2014CN04734A IN4734CHN2014A IN2014CN04734A IN 2014CN04734 A IN2014CN04734 A IN 2014CN04734A IN 4734CHN2014 A IN4734CHN2014 A IN 4734CHN2014A IN 2014CN04734 A IN2014CN04734 A IN 2014CN04734A
Authority
IN
India
Prior art keywords
cells
vectors
compositions
biologically active
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Kevin Polach
Jason Fewell
Khursheed Anwer
Lestlie S Wilkinson
Original Assignee
Egen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egen Inc filed Critical Egen Inc
Publication of IN2014CN04734A publication Critical patent/IN2014CN04734A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/85Fusion polypeptide containing an RNA binding domain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/50Biochemical production, i.e. in a transformed host cell
    • C12N2330/51Specially adapted vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/48Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN4734CHN2014 2011-12-23 2012-12-24 IN2014CN04734A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579815P 2011-12-23 2011-12-23
PCT/US2012/071576 WO2013096958A1 (en) 2011-12-23 2012-12-24 Compositions and methods for the delivery of biologically active rnas

Publications (1)

Publication Number Publication Date
IN2014CN04734A true IN2014CN04734A (ja) 2015-09-18

Family

ID=48654938

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4734CHN2014 IN2014CN04734A (ja) 2011-12-23 2012-12-24

Country Status (10)

Country Link
US (1) US20130164845A1 (ja)
EP (1) EP2794879A4 (ja)
JP (1) JP2015507474A (ja)
KR (1) KR20140123054A (ja)
CN (1) CN104169419A (ja)
AU (1) AU2012358181A1 (ja)
CA (1) CA2860228A1 (ja)
HK (1) HK1203548A1 (ja)
IN (1) IN2014CN04734A (ja)
WO (1) WO2013096958A1 (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11639371B2 (en) * 2016-02-17 2023-05-02 The Chinese University Of Hong Kong Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
WO2018132755A1 (en) * 2017-01-12 2018-07-19 Duke University Compositions and methods for disrupting the molecular mechanisms associated with mitochondrial dysfunction and neurodegenerative disease
RU2019143627A (ru) * 2017-06-28 2021-07-28 Юниверсити Оф Соус Флорида Модифицированный ген ube3a для генной терапии синдрома ангельмана
SG11202108645YA (en) * 2019-02-15 2021-09-29 Atreca Inc Antibodies that bind tumor tissue, and their diagnostic and therapeutic uses
CN114395576B (zh) * 2020-08-31 2023-11-14 南京工业大学 一种提高梭菌中蛋白表达效率的方法
CA3218711A1 (en) * 2021-05-13 2022-11-17 Roee Amit Methods and compositions for treatment of viral infection
WO2023182870A1 (ko) * 2022-03-24 2023-09-28 (주)셀레브레인 신규 재조합 벡터 및 이의 용도
EP4303305A1 (en) * 2022-07-07 2024-01-10 Kutzner, Christoph Fusion polypeptides for cell penetration and cell targeting

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) * 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
AU2003274906A1 (en) * 2002-07-31 2004-02-16 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
AU2003279004B2 (en) * 2002-09-28 2009-10-08 Massachusetts Institute Of Technology Influenza therapeutic
US20090004668A1 (en) * 2007-06-22 2009-01-01 The Board Of Trustees Of The Leland Stanford Junior University Pre-miRNA loop-modulated target regulation
WO2010105277A1 (en) * 2009-03-13 2010-09-16 Egen, Inc. Compositions and methods for the delivery of biologically active rnas
SI2539451T1 (sl) * 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna

Also Published As

Publication number Publication date
US20130164845A1 (en) 2013-06-27
EP2794879A1 (en) 2014-10-29
WO2013096958A1 (en) 2013-06-27
WO2013096958A8 (en) 2014-07-24
HK1203548A1 (en) 2015-10-30
CA2860228A1 (en) 2013-06-27
KR20140123054A (ko) 2014-10-21
CN104169419A (zh) 2014-11-26
AU2012358181A8 (en) 2015-06-18
AU2012358181A1 (en) 2014-07-10
JP2015507474A (ja) 2015-03-12
EP2794879A4 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
IN2014CN04734A (ja)
MX2020006065A (es) Metodos y productos para la produccion y administracion de acido nucleico.
JOP20210207A1 (ar) مركبات ترابطية مستهدفة
JOP20210231A1 (ar) مركبات ترابطية مستهدفة كمركبات علاجية
WO2013158309A3 (en) Non-disruptive gene targeting
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
MX346145B (es) Composición de sistema de suministro de arnsi in vivo basado en péptidos.
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
EP4241784A3 (en) Artificial nucleic acid molecules for improved protein expression
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
MX357803B (es) Moléculas de ácido nucleico artificiales.
MX358706B (es) Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
CA2863964C (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
MX2019002345A (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
MX342764B (es) Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas.
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
WO2019060522A3 (en) Thiomorpholino oligonucleotides for the treatment of muscular dystrophy
MX2013007543A (es) Composicion farmaceutica conteniendo l-adn.
MX2015005867A (es) Moleculas de transporte especificas de proteoglicano c4s.
WO2014006452A3 (en) Rapid alkalinization factor peptides for delivery of nucleic acid molecules into cells